CSIMarket Company Name, Ticker, Industry, else..
 
Iterum Therapeutics Plc  (NASDAQ: ITRM)
 
Price: $0.0683 $-0.01 -13.519%
Day's High: $0.06831999868154526 Week Perf: -8.91 %
Day's Low: $ 0.04 30 Day Perf: 127.73 %
Volume (M): 16,168 52 Wk High: $ 0.83
Volume (M$): $ 0 52 Wk Avg: $0.33
Open: $0.04 52 Wk Low: $0.00



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 46
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious and life-threatening infections. The company utilizes its expertise in antimicrobial drug development to create drugs that target specific pathogens and combat the growing problem of antibiotic resistance. Iterum Therapeutics is committed to addressing the unmet medical needs of patients and improving outcomes in the treatment of infectious diseases.


   Company Address: 25 North Wall Quay Dublin 1 0
   Company Phone Number: 1 903-8354   Stock Exchange / Ticker: NASDAQ ITRM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.43%    
BMY   -6.83%    
JNJ   -3.42%    
LLY   -3.53%    
MRK   -5.04%    
PFE   -4.46%    
• View Complete Report
   



Stock Market Announcement

Iterum Therapeutics Regains Nasdaq Compliance and Closes Successful Rights Offering, Fueling Growth in Antibiotic Development,

Published Thu, Nov 21 2024 1:30 PM UTC

Iterum Therapeutics Regains Full Nasdaq Compliance Amid Successful Rights OfferingIn an inspiring turn of events, Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to developing next-generation oral and intravenous (IV) antibiotics, has regained full compliance with Nasdaq listing standards. This milestone comes as a significant achiev...
Shares

Iterum Therapeutics Completes Successful Rights Offering, Paving the Way for Growth in Shareholder Value

Published Tue, Aug 6 2024 9:30 PM UTC


DUBLIN and CHICAGO, Aug. 06, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), a prominent clinical-stage pharmaceutical company specializing in the development of next-generation oral and IV antibiotics to combat infections caused by multi-drug resistant pathogens, announced today the expiration of the subscription period for its highly anticipated rights offering. This l...
Product Service News

Iterum Therapeutics Strengthens Market Position with New Patents for Oral Sulopenem

Published Fri, Aug 2 2024 12:00 PM UTC

DUBLIN and CHICAGO, Aug. 02, 2024 Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to the advancement of innovative oral and intravenous antibiotics, has announced significant progress in its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for two new U.S. pate...
Shares

Iterum Therapeutics Launches Rights Offering: A Promising Step Towards Combatting Multi-Drug Resistant Infections

Published Mon, Jul 22 2024 11:30 AM UTC



Iterum Therapeutics plc, a clinical-stage pharmaceutical company specializing in the development of advanced oral and IV antibiotics, has recently announced the commencement of its rights offering. This press release signifies a significant development for the company, amidst its ongoing efforts to tackle infections caused by multi-drug resistant pathogens in vario...
Clinical Study

Iterum Therapeutics Showcases Groundbreaking Antibiotic Research at ASM Microbe 2024 Conference

Published Wed, Jun 5 2024 12:00 PM UTC

Iterum Therapeutics plc, a leading clinical-stage pharmaceutical company specializing in the development of advanced oral and intravenous antibiotics to combat infections caused by multi-drug resistant pathogens, announced its participation in the prestigious American Society for Microbiology (ASM) Microbe 2024 meeting. The event, scheduled from June 13th to 17th in Atlanta,...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.79
Working Capital Ratio 2.23
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.83 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.24 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,497,833
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Iterum Therapeutics Plc's Segments

  Iterum Therapeutics Plc Outlook

On May 13 2024 the Iterum Therapeutics Plc provided following guidance

Iterum Therapeutics Plc. has recently reported their financial results for the first quarter of 2024. The company has resubmitted their New Drug Application (NDA) and is expecting action from the FDA in early Q4 2024. With a cash runway...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.